HUTCHMED (China) (HMDCF) Equity Income (2018 - 2019)
HUTCHMED (China)'s (HMDCF) quarterly Equity Income came in at $10.2 million in Q4 2019, up 23.05% year-over-year from $8.3 million in Q4 2018, and up 218.5% quarter-over-quarter from $3.2 million in Q3 2019.
Powered by 
Analysis
HUTCHMED (China) (HMDCF) Equity Income (2018 - 2019) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Equity Income for 2 consecutive years, with $10.2 million the latest figure, recorded in Q4 2019.
- On a quarterly basis, Equity Income rose 23.05% year-over-year to $10.2 million in Q4 2019; TTM through Dec 2019 was $40.7 million, a 110.52% increase from a year earlier, with the FY2025 full-year figure at $22.7 million, down 51.26% from the prior year.
- Equity Income was $10.2 million for Q4 2019 at HUTCHMED (China), up from $3.2 million in the prior quarter.
- Over five years, Equity Income peaked at $17.1 million in Q1 2019 and troughed at -$12.0 million in Q3 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.35 Bn | 198.36 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.19 Bn | 178.01 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.48 Bn | 124.62 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.59 Bn | 74.60 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.45 Bn | 56.27 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.89 Bn | 49.75 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.21 Bn | 30.90 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.38 Bn | 30.10 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.81 Bn | 29.81 Bn | 1.16 Mn | - |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | 10.19 Mn |
| Sep 30, 2019 | 3.20 Mn |
| Jun 30, 2019 | 10.20 Mn |
| Mar 31, 2019 | 17.11 Mn |
| Dec 31, 2018 | 8.28 Mn |
| Sep 30, 2018 | -12.00 Mn |
| Jun 30, 2018 | 8.02 Mn |
| Mar 31, 2018 | 15.03 Mn |